Why Did Cathie Wood Buy AMD?
Noted tech investor Cathie Wood has used the recent stock…
Sell
43
EKSO Quote, Financials, Valuation and Earnings
Last price:
$0.48
Seasonality move
:
-13.02%
Day range:
$0.48 - $0.50
52-week range:
$0.34 - $1.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.54x
P/B ratio:
0.94x
Volume:
69.1K
Avg. volume:
131.1K
1-year change:
-62.56%
Market cap:
$12M
Revenue:
$17.9M
EPS (TTM):
-$0.57
Analysts' Opinion
-
Consensus RatingEkso Bionics Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.00, Ekso Bionics Holdings has an estimated upside of 935.2% from its current price of $0.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 100% downside risk from its current price of $0.48.
Fair Value
-
According to the consensus of 1 analyst, Ekso Bionics Holdings has 935.2% upside to fair value with a price target of $9.00 per share.
EKSO vs. S&P 500
-
Over the past 5 trading days, Ekso Bionics Holdings has overperformed the S&P 500 by 6.17% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ekso Bionics Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ekso Bionics Holdings has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Ekso Bionics Holdings reported revenues of $5.1M.
Earnings Growth
-
Ekso Bionics Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ekso Bionics Holdings reported earnings per share of -$0.14.
Enterprise value:
10.6M
EV / Invested capital:
--
Price / LTM sales:
0.54x
EV / EBIT:
--
EV / Revenue:
0.59x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9.5M
Return On Assets:
-40.26%
Net Income Margin (TTM):
-63.21%
Return On Equity:
-85.45%
Return On Invested Capital:
-60.09%
Operating Margin:
-43.81%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $12.9M | $18.3M | $17.9M | $4.8M | $5.1M | |
| Gross Profit | $6.2M | $9.1M | $9.5M | $2.4M | $2.7M | |
| Operating Income | -$15.6M | -$15.1M | -$10.5M | -$3.4M | -$2.2M | |
| EBITDA | -$14M | -$13.2M | -$9.5M | -$2.7M | -$3M | |
| Diluted EPS | -$1.16 | -$1.10 | -$0.57 | -$0.22 | -$0.14 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $18.4M | $47.8M | $31M | $20.2M | $18.8M | |
| Total Assets | $20.6M | $49.2M | $40.9M | $28.9M | $26.7M | |
| Current Liabilities | $5M | $6.9M | $9.2M | $8.1M | $7.5M | |
| Total Liabilities | $16.2M | $11.9M | $15.5M | $16.3M | $13.9M | |
| Total Equity | $4.4M | $37.2M | $25.4M | $12.6M | $12.7M | |
| Total Debt | $3.1M | $2M | $6.1M | $6.1M | $5.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$14.7M | -$12.1M | -$9.8M | -$1.6M | -$1.4M | |
| Cash From Investing | -$5.2M | -$157K | -$37K | -$43K | -$21K | |
| Cash From Financing | -- | $348K | $7.8M | $348K | -$314K | |
| Free Cash Flow | -$14.9M | -$12.2M | -$9.9M | -$1.6M | -$1.5M | |
EKSO
Sector
Market Cap
$12M
$35.8M
Price % of 52-Week High
31.57%
45.38%
Dividend Yield
0%
0%
Shareholder Yield
-64.8%
-0.81%
1-Year Price Total Return
-62.56%
-38.89%
Beta (5-Year)
1.094
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.47
200-day SMA
Sell
Level
$0.78
Bollinger Bands (100)
Sell
Level
0.42 - 0.64
Chaikin Money Flow
Sell
Level
-45.1M
20-day SMA
Buy
Level
$0.42
Relative Strength Index (RSI14)
Buy
Level
59.71
ADX Line
Buy
Level
15.56
Williams %R
Sell
Level
-18.6335
50-day SMA
Buy
Level
$0.44
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
233.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.7624)
Sell
CA Score
(Annual)
Level (-2.2109)
Buy
Beneish M-Score
(Annual)
Level (-2.4677)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.1247)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Stock Forecast FAQ
In the current month, EKSO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EKSO average analyst price target in the past 3 months is $9.00.
-
Where Will Ekso Bionics Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ekso Bionics Holdings share price will rise to $9.00 per share over the next 12 months.
-
What Do Analysts Say About Ekso Bionics Holdings?
Analysts are divided on their view about Ekso Bionics Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ekso Bionics Holdings is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Ekso Bionics Holdings's Price Target?
The price target for Ekso Bionics Holdings over the next 1-year time period is forecast to be $9.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EKSO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ekso Bionics Holdings is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of EKSO?
You can purchase shares of Ekso Bionics Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ekso Bionics Holdings shares.
-
What Is The Ekso Bionics Holdings Share Price Today?
Ekso Bionics Holdings was last trading at $0.48 per share. This represents the most recent stock quote for Ekso Bionics Holdings. Yesterday, Ekso Bionics Holdings closed at $0.48 per share.
-
How To Buy Ekso Bionics Holdings Stock Online?
In order to purchase Ekso Bionics Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Salesforce Stock Drop After a Strong Quarter?
Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…
Is Adobe Stock a Bargain With AI Tools Driving Growth?
The share price of American computer software company Adobe (NASDAQ:ADBE)…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
4
CABO alert for May 3
Cable One [CABO] is down 41.98% over the past day.
Buy
55
PDEX alert for May 3
Pro-Dex [PDEX] is down 32.02% over the past day.
Buy
91
TRUP alert for May 3
Trupanion [TRUP] is up 23.52% over the past day.
